Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
Investment Conferences
Cantor Global Healthcare Conference (New York)Fireside Chat Sept. 5 8:00 am ET + 1x1 meetings
H.C. Wainwright Global Investment Conference (New York)Presentation Sept. 8 3:30 pm ET + 1x1 meetings
Morgan Stanley Global Healthcare Conference (New York)Fireside Chat Sept. 10 7:00 am ET + 1x1 meetings
Medical/Scientific Conferences
Obesity Science & Innovation (Boston)Keynote Panel Sept. 16 9:10 am ETTitle: Pipeline priorities - exploring leading and emerging targets shaping the future of obesity therapeutics
European Association for the Study of Diabetes Annual Meeting (EASD) (Vienna, Austria)Oral Presentation Sept. 19 10:15 am CETTitle: A multiple dose study to evaluate the safety and tolerability of nimacimab, a peripherally restricted, inhibitory CB1 receptor antibody in subjects with metabolic associated fatty liver disease (MAFLD)
Available webcasts will be accessible on Skye's website.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTSInvestor Relationsir@skyebioscience.com(858) 410-0266
LifeSci Advisors, Mike Moyermmoyer@lifesciadvisors.com(617) 308-4306
Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@lifescicomms.com(628) 234-3889
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. These forward looking statements include, but are not limited to: (i) statements regarding the superior safety and tolerability profile of nimacimab relative to other small molecule CB1 inhibitors, (ii) statements relating to any expectations regarding the efficacy and therapeutic potential of nimacimab as a monotherapy or in combination with a GLP-1 targeted drug, including expectations based on preclinical DIO models, (iii) statements regarding nimacimab's potential to change weight loss standards of care, (iv) statements regarding superior potency of nimacimab to other small molecule CB1 inhibitors based on nimacimab's mechanism of action and (v) statements regarding the timing of receipt of final data from Skye's Phase 2 obesity study of nimacimab. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
All Eyes on Powell: Will Jackson Hole Speech Spark a Big Stock Market Move?
Key Takeaways Traders expect the S&P 500 to move about 0.8% in either direction through the end of the week, with Fed Chair Jerome Powell's speech on Friday likely to be a driving force behind that move. Stocks jumped more than 1% the day of last year's Jackson Hole speech, when Powell signaled the Fed was ready to cut interest rates for the first time in 4 years. Analysts earlier this week expressed concern that investors were overly optimistic about the likelihood of a September rate cut, but expectations and stocks have drifted lower in recent days. Wall Street was on edge Thursday, with stocks trading lower as investors awaited what could be a pivotal policy speech from Federal Reserve Chair Jerome Powell. Powell is scheduled to speak Friday morning at the Fed's annual Jackson Hole Economic Policy Symposium. Investors will be scrutinizing Powell's address for signs that the Fed is ready to resume cutting interest rates in September after nine months on hold. Powell's speech is the biggest event of the week for the stock market, and traders are positioning themselves accordingly. Options pricing suggests investors expect the S&P 500 to move about 0.8% in either direction through the end of this week. That's nearly twice the S&P 500's average daily move over the past month. Will History Repeat Itself at Jackson Hole? At last year's Jackson Hole, Powell declared the Fed was ready to begin cutting interest rates more than a year after policymakers hiked rates for the 11th and final time in their post-pandemic policy tightening campaign. 'The time has come for policy to adjust,' Powell said. 'With an appropriate dialing back of policy restraint, there is good reason to think that the economy will get back to 2 percent inflation while maintaining a strong labor market.' It was the news Wall Street was hoping for. The S&P 500 jumped more than 1% to trade just shy of an all-time high. Though for investors last year, seeing was believing; it wasn't until mid-September, when the Fed cut rates for the first time, that the index finally broke its previous record. Rate Cut Expectations—and Stocks—Are Falling Evercore ISI analysts warned in a note on Sunday that Powell's speech could deliver stocks a rough patch if Wall Street finds his comments inadequately dovish. 'For a market that was eager to embrace '50 in Sept', a balanced view could catalyze a near term -7% to -15% pullback into October,' the analysts wrote, referring to recent speculation that the Fed could make a jumbo, 50 basis point (bps) cut next month. Deutsche Bank economists are also worried about Wall Street's high hopes. In a note earlier this week, they expressed concern that Powell's comments, which they expect to be 'more balanced' than his last statement in July, 'could create uncertainty about September cut prospects, at least relative to current elevated pricing.' But expectations and stock prices have moderated in recent days. The S&P 500 fell in each of the last four sessions. If the index declines on Thursday, it will mark its longest losing streak this year. And in the last week, traders have become less confident of any rate cut, let alone a jumbo one, in September. Federal funds futures trading data put the odds of a 25 bps cut at about 72% on Thursday, down from 92% a week ago, according to CME Group's FedWatch Tool. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Analog Devices Unlocks New Growth Engines In AI, Aerospace, And Robotics
Analog Devices (NASDAQ:ADI) delivered stronger-than-expected quarterly results on Wednesday and issued an upbeat outlook, signaling momentum across industrial and communications markets while highlighting new structural growth drivers in AI, aerospace, and automation. Following the results, JP Morgan analyst Harlan Sur maintained an Overweight rating on ADI and increased the price forecast from $300 to $310. Sur cited a stronger cyclical recovery and expanding secular drivers. He lifted his forward estimates, projecting fiscal 2026 EPS of ~$8.85, and applied a 35x multiple, the high end of peer group valuations, reflecting ADI's premium margins and diversified growth noted that July-quarter revenue rose 9% Q/Q to $2.88 billion, beating consensus of $2.765 billion, with EPS at $2.05 vs. $1.95 expected. Growth was broad-based: industrial climbed 11% Q/Q and 23% Y/Y, communications surged 18% Q/Q and 42% Y/Y on AI networking strength, and consumer rose 17% Q/Q and 20% Y/Y. Automotive stayed flat sequentially but gained 23% Y/Y due to product cycles and China demand pull-forward. For the October quarter, ADI guided revenue to $3.0 billion (up 4% Q/Q), topping consensus of $2.823 billion, with EPS of $2.22 vs. $2.03 expected and operating margin of 43.5% vs. 42.4% consensus. Industrial is expected to lead growth with low-to-mid-teens sequential gains, while automotive should decline in the low-teens Q/Q as earlier pull-forwards unwind. Sur highlighted ADI's structural growth engines, including aerospace & defense now trending above $1 billion annually (~10% of revenue), AI/datacenter opportunities in optical networking and power systems rising toward $550 million–$600 million annually vs. $400 million in fiscal 2024, and industrial automation tailwinds from humanoid robotics design wins. Sur also cited strong capital returns, with $3.7 billion in free cash flow (35% margin) over the past 12 months and $1.6 billion returned to shareholders via dividends and buybacks. Price Action: ADI stock is trading higher by 1.73% to $249.04 at last check Thursday. Photo via Shutterstock Latest Ratings for ADI Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Citigroup Maintains Buy Jan 2022 Barclays Maintains Overweight View More Analyst Ratings for ADI View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ANALOG DEVICES (ADI): Free Stock Analysis Report This article Analog Devices Unlocks New Growth Engines In AI, Aerospace, And Robotics originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
18 minutes ago
- Yahoo
Futu Holdings (FUTU) Ends 4-Day Losses on Stellar Earnings
We recently published . Futu Holdings Limited (NASDAQ:FUTU) is one of Wednesday's best performers. Futu Holdings snapped a four-day losing streak on Wednesday, jumping 6.01 percent to close at $178.66 apiece as investors cheered the company's stellar earnings performance in the second quarter of the year. In an updated report, Futu Holdings Limited (NASDAQ:FUTU) said net income more than doubled to HK$2.57 billion from HK$1.21 billion in the same period last year. Revenues grew by 69 percent to HK$5.3 billion from HK$3.13 billion year-on-year, on the back of higher brokerage commission and handling charge income, as well as increased interest income. Copyright: belchonock / 123RF Stock Photo In the first half, net income more than doubled to HK$4.7 billion from HK$2.24 billion, while revenues increased by 75 percent to HK$10 billion from HK$5.7 billion year-on-year. 'Trade policy-induced market volatility, coupled with a slate of high-profile IPOs, boosted retail sentiment in Hong Kong, which, for the third quarter in a row, contributed the highest number of new funded accounts across all markets. The US market also recorded solid growth. In the second quarter, we became the official sponsor of the New York Mets, further elevating our brand image in the US and beyond. We also launched crypto trading in most of the states in June, strengthening our value proposition as a one-stop trading platform,' said Futu Holdings Limited (NASDAQ:FUTU) Chairman and CEO Leaf Hua Li. While we acknowledge the potential of FUTU as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
